Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b tanezumab dose-ranging trial in interstitial cystitis/painful bladder syndrome
2009-014597-17Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) and chronic pain comparing Tanezumab dose-ranging arms with Placebo (2 arms). Primary endpoint: Change in mean average daily pain over 7 days at Week 16. Started Oct 2009; status: terminated.
02
Drugs
tanezumab
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)chronic pain
Beyond the preview
Go deeper on 2009-014597-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014597-17.